PreciseDx

company

About

PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology.

  • 1 - 10

Details

Last Funding Type
Series A
Last Funding Money Raised
$10.75M
Industries
Health Care
Founded date
Jan 1, 2019
Number Of Employee
1 - 10
Operating Status
Active

PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, enabling better and more personalized treatment and outcomes. Clinical teams can rely on PreciseDx for unmatched insights and actionable intelligence in determining the best treatment for each patient. Combining the power of artificial intelligence with its proprietary Morphology Feature Array™, PreciseDx creates disease-specific assays that deliver new levels of pathology information and insight on each patient's risk profile and likely outcomes to aid in treatment decision-making.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$10.75M
PreciseDx has raised a total of $10.75M in funding over 2 rounds. Their latest funding was raised on Jan 11, 2022 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 11, 2022 Series A $10.75M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
PreciseDx is funded by 1 investors. Agilent Technologies are the most recent investors.
Investor Name Lead Investor Funding Round
Agilent Technologies Series A